The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo ... shortly after the approval of GSK's recombinant RSVPreF3 ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

Respiratory Syncytial Virus Vaccine, Adjuvanted, contains recombinant RSV glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E ...

This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance for seniors. Carina Marquez, MD, associate professor of Medicine in ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

RSV vaccines effective, but more people need to get them Date: October 28, 2024 Source: University of Rochester Medical Center Summary: Doctors detail what we learned after the first season ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Credit: Getty Images Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD. While adults with IBD face a 2-fold increased risk for RSV ...

More information: Angela R Branche, Real-world effectiveness studies of the benefit of RSV vaccines, The Lancet (2024).DOI: 10.1016/S0140-6736(24)02150-0 Amanda B Payne et al, Respiratory ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...